Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PEN |
---|---|---|
09:32 ET | 3212 | 242.56 |
09:35 ET | 124 | 243.12 |
09:50 ET | 628 | 243.62 |
09:51 ET | 1799 | 243.7 |
09:53 ET | 1125 | 245 |
09:55 ET | 194 | 244.58 |
10:02 ET | 100 | 245.74 |
10:04 ET | 876 | 246.61 |
10:20 ET | 900 | 244.915 |
10:22 ET | 400 | 245.68 |
10:24 ET | 125 | 244.905 |
10:29 ET | 100 | 245.285 |
10:33 ET | 100 | 244.86 |
10:38 ET | 500 | 244.27 |
10:42 ET | 300 | 244.43 |
10:45 ET | 1367 | 244.42 |
10:47 ET | 1299 | 244.61 |
10:51 ET | 129 | 244.81 |
10:54 ET | 500 | 244.025 |
10:56 ET | 1470 | 244.67 |
10:58 ET | 226 | 244.64 |
11:03 ET | 100 | 243.965 |
11:05 ET | 100 | 243.94 |
11:07 ET | 400 | 244.12 |
11:09 ET | 200 | 244.09 |
11:12 ET | 100 | 243.9 |
11:14 ET | 200 | 243.645 |
11:16 ET | 200 | 243.74 |
11:21 ET | 300 | 243.77 |
11:23 ET | 200 | 244.07 |
11:25 ET | 200 | 244.08 |
11:27 ET | 160 | 244.137 |
11:34 ET | 221 | 243.85 |
11:36 ET | 100 | 243.665 |
11:38 ET | 1110 | 243 |
11:39 ET | 236 | 242.78 |
11:43 ET | 1147 | 242.76 |
11:45 ET | 226 | 242.53 |
11:48 ET | 1100 | 242.65 |
11:50 ET | 200 | 242.925 |
11:52 ET | 100 | 242.87 |
11:59 ET | 400 | 243.1 |
12:01 ET | 200 | 243.25 |
12:03 ET | 564 | 243.42 |
12:08 ET | 100 | 243.525 |
12:14 ET | 494 | 243.86 |
12:19 ET | 100 | 243.965 |
12:21 ET | 200 | 243.73 |
12:24 ET | 100 | 244.05 |
12:28 ET | 200 | 243.78 |
12:32 ET | 301 | 244.1 |
12:37 ET | 100 | 244.08 |
12:44 ET | 405 | 244.49 |
12:46 ET | 321 | 244.505 |
12:48 ET | 101 | 244.68 |
12:50 ET | 227 | 244.78 |
12:57 ET | 200 | 244.29 |
01:00 ET | 39317 | 244.12 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Penumbra Inc | 9.4B | 283.8x | +65.82% |
Masimo Corp | 9.2B | 118.7x | -15.37% |
Repligen Corp | 8.2B | -488.9x | +15.08% |
Bio Rad Laboratories Inc | 9.5B | -12.5x | --- |
Glaukos Corp | 7.9B | -48.5x | --- |
Teleflex Inc | 8.9B | 38.2x | +12.49% |
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.4B |
---|---|
Revenue (TTM) | $1.2B |
Shares Outstanding | 38.4M |
Penumbra Inc does not pay a dividend. | |
Beta | 0.51 |
EPS | $0.86 |
Book Value | $30.48 |
P/E Ratio | 283.8x |
Price/Sales (TTM) | 8.1 |
Price/Cash Flow (TTM) | 153.9x |
Operating Margin | 0.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.